Vergnolle Nathalie
INSERM, U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France.
Pharmacol Ther. 2009 Sep;123(3):292-309. doi: 10.1016/j.pharmthera.2009.05.004. Epub 2009 May 28.
Proteases have been shown to signal to cells through the activation of a novel class of receptors coupled to G proteins: the protease-activated receptors (PARs). Those receptors are expressed in a wide range of cells, which ultimately are all involved in mechanisms of inflammation and pain. Numerous studies have considered the role of PARs in cells, organ systems or in vivo, highlighting the fact that PAR activation results in signs of inflammation. A growing body of evidences discussed here suggests that these receptors, and the proteases that activate them, interfere with inflammation and pain processes. Whether a role for PARs has been clearly defined in inflammatory and pain pathologies is discussed in this review. Further, the pros and cons for considering PARs as targets for the development of therapeutic options for the treatment of inflammation and pain are discussed.
蛋白酶已被证明可通过激活一类与G蛋白偶联的新型受体向细胞发出信号:蛋白酶激活受体(PARs)。这些受体在多种细胞中表达,最终都参与炎症和疼痛机制。许多研究探讨了PARs在细胞、器官系统或体内的作用,突出了PAR激活会导致炎症迹象这一事实。本文讨论的越来越多的证据表明,这些受体以及激活它们的蛋白酶会干扰炎症和疼痛过程。本综述讨论了PARs在炎症和疼痛病理中的作用是否已明确界定。此外,还讨论了将PARs作为开发炎症和疼痛治疗选择靶点的利弊。